Collegium Pharmaceuticals Inc., a Cumberland, R.I.-based developer of late-stage drugs that add market value and clinical benefit to existing products, has raised $5.5 million in Series C funding, according to a regulatory filing. Backers include Boston Millennia Partners and Westfield Capital Management. www.collegiumpharma.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: